Daewoong Pharmaceutical Publishes Molecular Mechanism of Bersiporocin as an Antifibrotic in EMBO Molecular Medicine
- Written by PR Newswire
![]() |
- Elucidated molecular mechanism behind safety and efficacy of Bersiporocin
- Bersiporocin is currently in Phase II clinical trial for Idiopathic Pulmonary Fibrosis
SEOUL, South Korea, May 26, 2023 /PRNewswire/ -- Daewoong Pharmaceutical (CEO Lee Chang-jae and Jeon Sengho) announced on the 25th that the molecular mechanism behind safety and efficacy of...















